Literature DB >> 29409372

Is iguratimod effective in refractory axial spondyloarthritis?

Y Luo1, N Zheng1, R Wu1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29409372     DOI: 10.1080/03009742.2017.1390150

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  5 in total

Review 1.  Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.

Authors:  Suling Liu; Yang Cui; Xiao Zhang
Journal:  Clin Rheumatol       Date:  2020-06-06       Impact factor: 2.980

Review 2.  Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.

Authors:  Jie Li; Jun Bao; Jian Zeng; Aizhu Yan; Chunqiu Zhao; Qiang Shu
Journal:  Bone Res       Date:  2019-09-03       Impact factor: 13.567

Review 3.  Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.

Authors:  Angela Ceribelli; Francesca Motta; Matteo Vecellio; Natasa Isailovic; Francesco Ciccia; Carlo Selmi
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 4.  Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.

Authors:  Sisi Xie; Shu Li; Jing Tian; Fen Li
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

5.  Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis.

Authors:  Yan Li; Kunpeng Li; Zheng Zhao; Yanyan Wang; Jingyu Jin; Junhua Guo; Jie Zhang; Jianglin Zhang; Jian Zhu; Feng Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.